🟢 ProMIS Neurosciences is trading 12.7% up today after Chardan initiated coverage with a Buy rating and $20 price target

ProMIS Neurosciences is trading 12.7% up at $13.21 following a sharp after-hours relief bounce triggered by a Buy rating initiation from Chardan.

• Chardan set a $20.00 price target for the stock, highlighting significant upside potential and the company’s Alzheimer’s program.
• The move follows several weak trading sessions and reflects renewed investor optimism in a relatively quiet macro environment.